The code-named 'RCI002' that this company has recently been researching and developing is a project to create a protein therapeutic with pain-relieving effects. This treatment is produced by synthesizing a protein gene in E. coli, expressing it, and then extracting the therapeutic substance. The approach involves optimizing a protein found in vivo and recombining it into a therapeutic capable of suppressing pain in the body over a prolonged period.
The company explained that this substance demonstrated a pain-free duration nearly 20 times longer than gabapentin — a pain reliever commonly administered in general hospitals for 慢性疼痛 management. When 65 mg/kg of gabapentin (based on body weight) was administered to mice, 疼痛缓解 lasted about 4 hours, but when only 0.1 mg/kg of the RCI002 substance was administered, 疼痛缓解 lasted approximately 3 days.
RudaCure is developing a 基因治疗 approach that relieves and treats 慢性疼痛 using a protein gene that regulates 慢性疼痛 in vivo. This is because a single injection can be expected to provide therapeutic effects for 2–3 years. CEO Kim stated, "Pain relievers, local anesthetics, and 麻醉性镇痛药 used in general hospitals are not fundamental treatments," adding, "Narcotic 镇痛s lose their effectiveness as 耐药性 develops or cause 成瘾性."